Skip to Content

Becton Dickinson & Co

BDX: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$362.00RxdwxfYbcngjqlf

Becton, Dickinson's 2022 Success Depends on Alaris

Business Strategy and Outlook

While 2020 was a challenging year for Becton, Dickinson, or BD, 2021 has been better, buoyed by Veritor demand in particular. Much uncertainty resides in the return of BD's pump infusion system (Alaris) to the market, which could be a material catalyst for the company that will see some challenging comps as testing revenue wanes.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of BDX so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center